Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT1-MMP Bicycle Imaging Agent
- Development stage
- Unknown
- Lead developer
- Bicycle Therapeutics
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Administration
- Intravenous
01
Overview
The MT1-MMP Bicycle Imaging Agent is a diagnostic radiopharmaceutical developed by Bicycle Therapeutics using their proprietary bicyclic peptide (Bicycle) platform. The agent is designed to target Matrix Metalloproteinase-14 (MT1-MMP, also known as MMP14), a transmembrane proteinase that plays a critical role in extracellular matrix degradation, tumor cell invasion, and angiogenesis. Highly expressed in a variety of solid tumors—including non-small cell lung cancer (NSCLC), breast cancer, and ovarian cancer—MT1-MMP serves as a biomarker for aggressive disease. This imaging agent is primarily developed as a companion diagnostic to support the clinical development of MT1-MMP-targeted therapeutics, such as the Bicycle Toxin Conjugate (BTC) BT1718. By utilizing PET or SPECT imaging (often labeled with isotopes like Gallium-68), the agent allows for the non-invasive quantification of MT1-MMP expression in the tumor microenvironment, enabling a precision medicine approach to patient selection.
- Other names
- MT1-MMP BicycleMT-1-MMP BicycleMT 1-MMP BicycleMT1-MMP Bicycle TracerMT-1-MMP Bicycle TracerMT 1-MMP Bicycle Tracer
02
Targets
MMP14 (Matrix metalloproteinase 14)
Beyond the preview
Go deeper on MT1-MMP Bicycle Imaging Agent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT1-MMP Bicycle Imaging Agent.